Thelansis’s "Autosomal Dominant Optic Atrophy (ADOA) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Autosomal Dominant Optic Atrophy treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
Autosomal dominant optic atrophy (ADOA) is a rare hereditary disorder characterized by progressive and irreversible vision loss in both eyes, typically commencing in the first decade of life. Around 80% of affected individuals manifest symptoms before the age of 10, with onset frequently occurring between the ages of 4 and 6. Hallmark clinical features of ADOA include central visual field defects and impaired color vision. The disease exhibits significant phenotypic variability among family members, making it challenging to predict the decline and progression of visual acuity. Many affected children eventually progress to blindness. About 50% of individuals with ADOA do not meet driving standards, and up to 46% are classified as legally blind. A subset of approximately 20% of patients presents with a more severe phenotype known as ADOA “plus” syndrome, which encompasses additional non-ocular manifestations such as permanent hearing loss and other severe conditions impacting the nervous system and skeletal muscles.
G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)
*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.
1. Key Findings and Analyst Commentary
2. Disease Context
3. Epidemiology
4. Market Size and Forecast
5. Competitive Landscape
6. Unmet Need and TPP Analysis
7. Regulatory and Reimbursement Environments (by country and payer insights)
8. Appendix (e.g., bibliography, methodology)
No snapshots available.
That depends on the file type you choose: the Excel epidemiology model, the Excel market forecast model with dashboard, and the full analyst report in PowerPoint with a PDF version.
Within 48 to 72 hours of purchase.
Yes. Choose EU5, G7 or G8, or pick individual markets in the panel.
Yes. Request a free sample to preview the scope and sample pages.
Yes. The forecast model is customizable, and our analysts can tailor the scope to your questions.
Yes. Inquire for bundle discounted pricing and we will send you exclusive pricing for the reports you need.
Choose the file type you want to purchase or request.
No file type found.
Select markets to include.
No markets match your search.
Not sure which report fits your question? Our team will point you to the right one.
Tell us what you are looking for and we will tailor the research to your indication, markets and questions.
Prefer to talk it through? Email clientsupport@thelansis.com
You asked for for covering . We will reply to .
Fill in your details and our expert consultants will get in touch with you.
Get a sneak peek at the latest Autosomal Dominant Optic Atrophy (ADOA) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034 report
Our team will get in touch with you shortly about the Autosomal Dominant Optic Atrophy (ADOA) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034 report.